Detalles de la búsqueda
1.
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Ann Hematol;
93(7): 1167-76, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24658964
2.
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Blood;
115(10): 1880-5, 2010 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-19965667
3.
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
J Clin Oncol;
32(5): 415-23, 2014 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24297946
4.
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
J Clin Oncol;
29(12): 1634-42, 2011 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21422420
Resultados
1 -
4
de 4
1
Próxima >
>>